Rondo Therapeutics

Rondo Therapeutics is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing next-generation T-cell engaging bispecific antibodies for the t

reatment of solid tumors. Founded between 2019 and 2021 by Shelley Force Aldred and Nathan Trinklein, the company aims to create tumor-selective therapies that effectively eradicate tumors while protecting healthy tissue. The company’s core technology platform utilizes a proprietary CD28 co-stimulatory system to enhance T-cell activity within the tumor microenvironment. Rondo's pipeline includes bispecific antibody drugs, such as RNDO-564, targeting bladder cancer, and a second candidate for additional solid tumor indications. Rondo Therapeutics has raised $67 million in funding, with notable investors including Novo Holdings and Johnson & Johnson Innovation. The company is also collaborating with Eli Lilly and Company to further develop its innovative therapies.